Adeniyi Olagunju

List of Publications by Year
in descending order

42 papers	548 citations	567144 15 h-index	713332 21 g-index
44 all docs	44 docs citations	44 times ranked	681 citing authors

#	Article	IF	Citations
1	Pharmacogenetics of pregnancy–induced changes in efavirenz pharmacokinetics. Clinical Pharmacology and Therapeutics, 2015, 97, 298-306.	2.3	39
2	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. Journal of Antimicrobial Chemotherapy, 2015, 70, 555-561.	1.3	35
3	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clinical Infectious Diseases, 2015, 61, 453-463.	2.9	32
4	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1013-1019.	1.3	30
5	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clinical Pharmacology and Therapeutics, 2021, 110, 36-48.	2.3	29
6	A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography–Mass Spectrometry. Therapeutic Drug Monitoring, 2015, 37, 220-228.	1.0	28
7	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. British Journal of Clinical Pharmacology, 2016, 82, 185-198.	1.1	28
8	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. Clinical Pharmacology and Therapeutics, 2017, 102, 529-536.	2.3	28
9	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology, 2013, 1, 4.	1.8	26
10	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics, 2012, 13, 1501-1522.	0.6	23
11	Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC–MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1060, 300-307.	1.2	23
12	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenetics and Genomics, 2014, 24, 459-463.	0.7	21
13	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. Journal of Antimicrobial Chemotherapy, 2015, 70, 2816-2822.	1.3	21
14	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. European Journal of Pharmaceutical Sciences, 2019, 140, 105068.	1.9	17
15	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
16	Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. Clinical Pharmacokinetics, 2020, 59, 1185-1194.	1.6	16
17	Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2015, 70, 3074-3079.	1.3	11
18	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 0, 1, 16.	1.5	11

#	Article	IF	Citations
19	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology, 2013, 8, 871-890.	0.9	10
20	CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. Therapeutic Drug Monitoring, 2014, 36, 734-738.	1.0	10
21	Pregnancy affects nevirapine pharmacokinetics. Pharmacogenetics and Genomics, 2016, 26, 381-389.	0.7	10
22	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
23	Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy, 2018, 73, 165-172.	1.3	8
24	Quality of artemisinin-based antimalarial drugs marketed in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 90-96.	0.7	8
25	Pharmacogenetics of artemether–lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?. British Journal of Clinical Pharmacology, 2019, 85, 540-550.	1.1	6
26	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. Aids, 2021, 35, 1919-1927.	1.0	6
27	Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. Pharmacogenomics, 2016, 17, 891-906.	0.6	5
28	Influence of *SLCO1B1* polymorphisms on lopinavir C_{trough} in Serbian HIV/AIDS patients. British Journal of Clinical Pharmacology, 2020, 86, 1289-1295.	1.1	5
29	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 3.	0.7	5
30	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics, 2019, 20, 217-223.	0.6	4
31	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by *CYP2B6* c.516G>T Genotypes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
32	Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. Journal of Antimicrobial Chemotherapy, 2020, 75, 1267-1271.	1.3	4
33	Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester. Frontiers in Pediatrics, 2021, 9, 734122.	0.9	4
34	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. Wellcome Open Research, 0, 4, 34.	0.9	4
35	*CYP2B6**6 Genotype Specific Differences in Artemether–Lumefantrine Disposition in Healthy Volunteers. Journal of Clinical Pharmacology, 2020, 60, 351-360.	1.0	3
36	Validation and Clinical Application of a Liquid Chromatography–Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots. Therapeutic Drug Monitoring, 2022, 44, 430-437.	1.0	3

#	Article	IF	Citations
37	Pharmacokinetics of HIV therapies in pregnant patients: an update. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 449-461.	1.5	2
38	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenetics and Genomics, 2020, 30, 96-106.	0.7	1
39	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 0, 6, 246.	0.9	1
40	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 0, 6, 246.	0.9	1
41	Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS Research and Therapy, 2022, 19, .	0.7	1
42	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 0, 6, 246.	0.9	0